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This study was conducted to demonstrate whether puerarin regulates glutamine synthetase (GS) 
activity following intraocular hypertension and has therapeutic potential in ophthalmology for the 
protection of optic nerves in patients with glaucoma. This study used a Wistar rat model of acute 
closed-angle glaucoma to investigate the effect of puerarin on GS activity in rat retina following 
intraocular hypertension. Acute intraocular hypertension was induced by increasing anterior chamber 
pressure to 110 mmHg for 30 min in the left eyes of 50 Wistar rats, while 5 additional Wistar rats lacking 
intraocular hypertension were used as a control group. Retinal GS activity was measured at 4, 12, 24, 36 
and 72 h after induction of acute intraocular hypertension with/without puerarin treatment. Compared to 
the control group that lacked intraocular hypertension, GS activity in the intraocular hypertension 
group significantly decreased at 4 and 12 h (P<0.01), before increasing at 24 to 36 h and restoring to a 
level similar to the control group at 72 h. However, puerarin significantly (P<0.05) prevented the loss of 
GS activity seen in the intraocular hypertension group at 4 and 12 h, with no significant (P<0.05) 
difference in GS activity noted between the control group and rats treated with puerarin at these early 
time points. GS activity significantly (P<0.05) increased above control values at 24 and 36 h in the 
puerarin-treated group before eventually restoring to control levels at 72 h. These findings suggest 
puerarin protects GS activity in the early stages of retinal acute intraocular hypertension and may be of 
potential therapeutic benefit in acute closed-angle glaucoma. 
 





Puerarin is one of several isoflavones found in a number 
of plants and herbs in East Asia, including the root of 
Pueraria, notably the leguminous kudzu plant (Radix 
puerariae) (Yeung et al., 2006).  Puerarin (4, 7- dihydroxy 
-8-β-D glucose isoflavone) is typically purified from dried 
root extracts of kudzu. Puerarin has been shown to dilate 
coronary and cerebral vascular smooth muscle, reduce 
vascular resistance and myocardial oxygen consumption,
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improve myocardial contractility and microcirculation 
function, and inhibit platelet aggregation (Tam et al., 
2009). Puerarin has been used in clinical practice to treat 
human diseases including ischemic heart disease and 
cerebrovascular/retinal diseases (Zhang et al., 2018; Liu 
et al., 2018). In the treatment of retinal diseases, puerarin 
crosses the blood-ocular barrier into the aqueous, 
vitreous region of the eye (Wong et al., 2011; Song et al., 
2020). Mechanisms of action reported for puerarin 
include inhibition of adenylate cyclase, stimulation of 
antioxidant activity (Zhao et al., 2015; Zhou et al., 2014; 
Xu et al., 2016), induction of superoxide dismutase 
activity, enhancement of p450 activity, improvement in 
ocular microcirculation, inhibition of Ca
2+
 influx through 
calcium channels (Song et al., 2020; Li et al., 2017) and 
enhancement of anti-apoptotic activities (Li et al., 2008; 
Yu et al., 2009; He et al., 2009).  Puerarin has also been 
promoted as a therapeutic strategy for diabetic 
nephropathy by reducing serum levels of tumour necrosis 
factor-alpha (TNF-α) and interleukin-6 (IL-6) (Xu et al., 
2016; Wang et al., 2014). Furthermore, puerarin acts as 
an anti-inflammatory agent by blocking nuclear factor-
kappa beta (NF–kB) signalling, suggesting it may be a 
useful prophylactic therapy for the prevention of 
atherosclerosis (Yang et al., 2010). Glutamine synthetase 
(GS) is the key enzyme in the glutamic acid-glutamine 
cycle and it plays an important role in protecting the optic 
nerves by reducing the extracellular concentration of 
glutamic acid (glutamate). Glutamate is a major excitatory 
neurotransmitter that participates in neuron signalling by 
activating a variety of ionotropic and metabotropic 
glutamate receptors in the mammalian central nervous 
system and retina. Glutamate-induced excitotoxicity has 
been proposed to mediate the death of retinal ganglion 
cells in glaucoma (Moreno et al., 2005).  
Furthermore, altered GS activity has been found in 
many kinds of human diseases, including diabetic retinal 
disease, epilepsy and ischemic optic nerve disease 
(Moreno et al., 2005; Sáenz et al., 2004). Under normal 
physiological circumstances, retinal extracellular 
glutamate is taken up by GS-expressing Müller cells that 
carry out the transformation of glutamate to glutamine 
(Zhang et al., 2014).  
However, conditions that reduce GS levels or activity 
would decrease this glutamate metabolism and might 
result in detrimental increases in extracellular glutamate 
concentration. Thus, this study investigated the effect of 
puerarin on GS activity during acute intraocular 
hypertension in a Wister rat model of acute closed-angle 
glaucoma to assess whether puerarin could provide 
retinal/optic nerve protection. Puerarin reversed the 
inhibition of GS activity induced by acute high intracellular 
pressure, suggesting puerarin has therapeutic potential in 
ophthalmology for the protection of optic nerves in the 
treatment of glaucoma. The precise mechanism by which 
puerarin provides this protection against acute high 














All animal studies and experimental procedures were approved by 
the Ethical Committee at Weifang People’s Hospital, Weifang, 
China. Healthy, eight-week-old Wistar rats were supplied by the 
Animal Research Centre, Weifang Medical University, Weifang, 
China. The Wistar rats were kept in ventilated cages and 
maintained in a temperature-controlled room with a 12:12 h 
light:dark schedule and provided with free access to water and 
standard rat pelleted diet ad libitum. 
 
 
Puerarin treatment and retinal tissue preparation 
 
A total of 55 pure-bred healthy Wistar rats (200-250 g) of either sex 
were divided randomly into 11 units (5 rats per unit) and allocated 
to the following three groups: control group (1 unit) that had 
healthy/normal characteristics and lacked the application of 
intraocular hypertension; intraocular hypertension group (5 units) 
lacking puerarin treatment and consisting of one unit (5 rats) per 
experimental time point (4, 12, 24, 36 and 72 h); and puerarin-
treated intraocular hypertension group (5 units) again consisting of 
one unit (5 rats) per experimental time point (4, 12, 24, 36 and 72 
h). Experiments were conducted in accordance with standard 
approved laboratory conditions for animal experiments. No eye 
diseases were present in any of the animals, and the left eyes were 
used throughout the experiment. The acute high intraocular 
pressure model was generated by left eye anterior chamber 
pressure perfusion. The rats were anaesthetised by intraperitoneal 
injection of 0.8 ml of 10% chloral hydrate. Puerarin (100 mg/kg, 
Enbei Pharmaceutical Co. Ltd, Zhejiang, China) was administered 
to the puerarin-treated intraocular hypertension group by slow 
intravenous injection into each rat’s tail 30 min before applying 
intraocular pressure. A similar sham intravenous injection was 
applied to the control and intraocular hypertension groups but no 
puerarin was administered. To induce high intraocular hypertension, 
an acupuncture needle was inserted into the left eye anterior 
chamber, and saline was infused for 30 min using a saline infusion 
bottle set to 150 cm (corresponding to a pressure of 110 mmHg). In 
the sham-treated control group, an acupuncture needle was 
inserted into the left eye anterior chamber and left in place for 30 
min without infusing any saline. All the rats were then euthanised 
using excess chloral hydrate at 4, 12, 24, 36 or 72 h after 
intraocular pressure was applied. The eyes were removed quickly, 
the cornea cut out and the crystal vitreous removed. The retina was 





Rat retinal tissue was placed into a mortar with some liquid 
nitrogen, and a pestle used to slowly grind the tissue. The tissue 
was then placed in ice-cold homogenate lysis buffer (Tris-
hydrochloride (Tris-HCl), NP-40, sodium chloride (NaCl), 
ethylenediaminetetraacetic acid (EDTA), sodium azide (NaN3) and 
PMSF protease inhibitor at pH 7.5) and homogenised for 10 cycles 
on ice (each cycle consisted of vortex mixing followed by sonication 
of the tissue homogenate for 2 min).  Subsequently, the samples 
were centrifuged at 10,000×g for 10 min at 4°C prior to collecting 





Protein assay  
 
The concentrations of protein were measured using the Bio-Rad 
protein assay according to the method described by the 
manufacturer (Bio-Rad). The concentration of total protein in 





The GS detection kit was supplied by Jiancheng Biological 
Engineering Institute, Nanjing, China. The kit was based on a 
colorimetric reaction between glutamine and hydroxylamine which 
can generate T-glutamyl hydroxamate and ammonia in the 
presence of GS. The latter was measured by its absorbance (Ab) at 
595 nm and GS activity in each sample was determined according 
to the manufacturer’s protocol using the equation: 
 
GS activity (U/mg) = (sample Ab - blank Ab)/(standard Ab - blank 





The data were analysed using SPSS 11.0 software and presented 
as mean ± standard deviation (SD) for at least three experiments. 
Univariate analysis of variance was used to detect the overall 
statistical difference between the groups as a whole. Dunnett’s t-
test for comparison of two groups was subsequently applied to 
make pair-wise comparisons between the experimental groups. A 




RESULTS AND DISCUSSION 
 
In this study, the influence of puerarin on GS activity after 
acute high intraocular pressure was investigated. The 
study utilised an established acute high eye pressure 
model in rats to explore differences in GS expression with 
time. GS activity (U/mg of protein; mean ± SD, n = 5) was 
monitored at 4, 12, 24, 36 and 72 h after left eye acute 
intraocular high-pressure application, with and without the 
puerarin injection. GS activity was down-regulated after 
acute intraocular hypertension in the left eyes at 4 and 12 
h (P<0.01) compared to the normal control (Table 1 and 
Figure 1), albeit an increase between 4 and 12 h. GS 
activity in the high intraocular hypertension group 
recovered to a similar level to that in the control group 
(P>0.05) at 24 h.  
Interestingly, GS activity became significantly greater in 
the high intraocular hypertension group than in the 
control group (P<0.01) at 36 h, before returning to similar 
levels as the control group at 72 h.  
Puerarin treatment reversed the inhibitory effects of 
high intraocular hypertension on GS activity at 4 and 12 
h, with no significant differences in GS activity detected at 
4 and 12 h compared to the control group. Indeed, GS 
activity was significantly (P<0.01) higher in the puerarin- 
treated group compared to the non-puerarin treated high 
intraocular hypertension group at 4, 12 and 24 h. GS 
activity   became   significantly   greater   in   the  puerarin  




group than the control group (P<0.01) at 24 and 36 h, 
peaking at 36 h before returning to similar levels as the 
control group at 72 h.  
The results suggest acute high intraocular pressure 
initiates a self-protection response in rats, whereby GS 
activity is subsequently restored after an initial period of 
inhibition. These findings are consistent with those 
reported in the literature. Early (<24 h) inhibition followed 
by significant elevation of GS activity that gradually 
returned to normal levels has been previously 
demonstrated in rat models of high intraocular pressure 
(Gui  et al., 2007; Shen et al., 2004). Elevated intraocular 
pressure has been shown to suppress early activity and 
expression of GS in an ex vivo rat model, leading to 
glutamate-associated excitotoxicity in rat retinal ganglion 
cells (Ishikawa et al., 2011). However, this study has 
shown puerarin treatment can reverse the early (<24 
hours) inhibition of GS activity, suggesting it may limit 
retinal injury caused by early acute intraocular high 
pressure. The stimulation of GS activity by puerarin is 
likely to protect retinal ganglion cells from glutamate-
mediated damage and/or apoptosis by promoting the 
conversion of glutamate into glutamine. Indeed, several 
studies have shown that excessive glutamate is an 
important mechanism in glaucoma optic nerve damage 
(Ishikawa et al., 2011; Otori et al., 1998; Asai et al., 
2000). However, although an increase in GS activity may 
be indicative of increased enzyme levels and subsequent 
substrate turnover; future work will need to confirm 
whether puerarin acts by inducing GS gene transcription 
or via some other mechanism. Interestingly, high 
intraocular pressure for 24 h has been shown to inhibit 
the expression of a key glutamate transporter in the retina 
called glutamate aspartate transporter (GLAST) and it is 
this impairment of GLAST that likely results in the 
downregulation of GS activity (Ishikawa et al., 2011). 
Thus, it feasible puerarin may indirectly increase early 
GS activity following high intraocular pressure through its 
action on an intermediary such as GLAST.  
 
 
Limitations of the study 
 
(1) This study has shown that puerarin protects GS 
activity in a rat model of retinal acute intraocular 
hypertension. However, the precise mechanism of action 
by which puerarin achieves this has not been determined. 
Thus, future work will focus on molecular investigations to 
elucidate these underlying mechanisms, together with 
histopathological (e.g. retinal ganglion cell damage) and 
biochemical (e.g. glutamate-glutamine) analyses to 
provide supporting evidence for our initial findings.  
(2) This study measured GS activity but did not determine 
mRNA expression. There was insufficient tissue available 
within the scope and budget constraints of this 
preliminary investigation to extract enough high quality 
protein and RNA from samples.  Thus, it was not possible  




Table 1. Glutamine synthetase (GS) activity (U/mg protein) in rats with intraocular hypertension with/without puerarin treatment at time T 
(hours; h).  
 
Group 




Hypertension Hypertension + Puerarin 

























































Indicates significant differences compared to the control group whereas stated P values indicate probability values when comparing the 




to confirm whether observed differences in GS activity 
are a reflection of changes at the level of gene transcription 
or subsequent protein synthesis/degradation. Future work 
will determine whether puerarin treatment induces 
expression of GS mRNA, either directly or via an 
intermediary following early high intraocular pressure.  
(3) The experimental control group consisted of 1 unit (5   
rats) rather than 5 units (25 rats). The number of rats 
used in this healthy control group was actively kept to a 
minimum (5 rats) to be consistent with  the 3 Rs  principle 
(Replacement/Reduction/Refinement) in the animal 
ethics application, thereby minimizing humane animal 
usage in the experiments wherever possible. Previous 
investigations, in addition to the present findings, have 
shown that GS activity and expression remains relatively 
unchanged over time in untreated, healthy control sets of 
rats (Moreno et al., 2005; Shen et al., 2004). Thus, there 
was limited merit in utilizing another large untreated 
control group consisting of 25 rats given the consistency 
in GS activity  in  this group. In contrast, 5 rats (1 unit) per  






Figure 1. Glutamine synthetase (GS) activity (U/mg of protein) at time T (h) in rats with intraocular hypertension 
with/without puerarin treatment. *Indicates significant (P<0.05) differences between intraocular hypertension 




time point were deemed necessary in the other two 
groups where intraocular hypertension had been applied 
given this factor was being investigated in our hypothesis 





This is the first study to confirm puerarin prevents the 
early inhibition of GS activity caused by high intraocular 
hypertension, suggesting it may protect against 
glutamate-induced excitotoxicity in glaucoma. Indeed, the 
findings are supported by clinical evidence that puerarin 
may be effective in the treatment of glaucoma (Kang, 
1993; Xu et al., 2010). Further detailed investigations are 
now required to confirm this hypothesis in other animal 
models and human studies, together with experiments to 
interrogate the precise mechanisms of action of puerarin. 
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